Johnson & Johnson (JNJ) valuation
Johnson & Johnson P/E ratio history
Johnson & Johnson trades at 41.5 times its earnings over the last twelve months and 23.8 times the earnings analysts expect over the next twelve. At its last 10 fiscal year ends its P/E ranged from 11.4 (year to Dec 2023) to 358.3 (year to Dec 2017), with a median of 23.9.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 28, 2025 | $207.63 | $11.03 | 18.8 | 18.3 |
| Dec 29, 2024 | $145.05 | $5.79 | 25.1 | 13.9 |
| Dec 31, 2023 | $156.74 | $13.81 | 11.4 | 14.5 |
| Jan 1, 2023 | $176.65 | $6.74 | 26.2 | 17.1 |
| Jan 2, 2022 | $171.07 | $7.81 | 21.9 | 16.7 |
| Jan 3, 2021 | $157.38 | $5.51 | 28.6 | — |
| Dec 29, 2019 | $145.75 | $5.63 | 25.9 | — |
| Dec 30, 2018 | $127.27 | $5.61 | 22.7 | — |
| Dec 31, 2017 | $139.72 | $0.39 | 358.3 | — |
| Jan 1, 2017 | $115.21 | $5.93 | 19.4 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Johnson & Johnson valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Johnson & JohnsonJNJ | $658B | 41.5 | 23.8 | 6.6 |
| MerckMRK | $369B | 119.6 | 25.0 | 5.6 |
| Eli LillyLLY | $1.33T | 46.0 | 31.0 | 15.4 |
| Novo NordiskNVO | $178B | 9.9 | — | 3.5 |
| PfizerPFE | $174B | 40.2 | 10.5 | 2.7 |
| Bristol Myers SquibbBMY | $128B | 13.8 | 9.5 | 2.6 |
| ZoetisZTS | $33.4B | 13.0 | 12.6 | 3.5 |
| ViatrisVTRS | $22.2B | — | 7.3 | 1.5 |
| Corcept TherapeuticsCORT | $8.71B | 193.1 | 25.7 | 10.5 |
| Peer median | 40.2 | 12.6 | 3.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: JNJ financials · JNJ returns
No forecast, no recommendation. This page describes Johnson & Johnson from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.